YCBD 最新10-Q变化
将 YCBD 最新的定期申报(10-K/10-Q)与上一份同类型申报逐章节对比:每个章节新增/删除的段落数与原文摘录。全部为确定性文本对比——无相似度评分、无方向判断、非投资建议。
对比:10-Q · 2026-08-13 与上一份 10-Q · 2026-05-14
| 章节 | 结果 | 新增 | 删除 | 微调 | 未变 |
|---|---|---|---|---|---|
| 管理层讨论与分析 | 文字有新增/删除 | +15 | −15 | ~14 | 26 |
| 控制与程序 | 无段落级文字变化 | 0 | 0 | 0 | 2 |
| 法律诉讼 | 无段落级文字变化 | 0 | 0 | 0 | 1 |
| 风险因素 | 公司称无重大变化(指向 10-K) | — | — | — | — |
| 其他信息 | 文字有新增/删除 | 0 | 0 | ~1 | 1 |
计数单位为段落;"新增/删除"指相对上一份文件新增/删除的文字,不含方向或好坏判断。
未列出(无法可靠提取或缺失):市场风险(第3项)
代表性摘录
每个章节最多 5 条、每条约 300 字符的原文摘录,直接来自两份 SEC 文件。
管理层讨论与分析
相对上期新增的文字 · 来源:10-Q · 2026-08-13
Management continues to pursue other M&A activity and incurred over $100,000 in legal and due diligence expenses on pursuing other transactions that would further diversify the Company's revenue and mitigate certain regulatory risks facing the hemp industry.
Numerous bills in the 119th Congress would repeal, delay, or modify Section 781 of Public Law 119-37 or establish a federal framework for hemp-derived cannabinoid products, including H.R. 6209, H.R. 7024/S. 3686, S. 3474, H.R. 7212, and S. 4315, none of which has advanced beyond committee. Most prom…
We remain focused on positioning the Company for a changing regulatory landscape. During the second and third quarters, we made progress on the following key initiatives:
Revenue Maximization: At the end of the third quarter, we added South Carolina distribution for Oasis and transitioned to a new distribution partner in Texas, which more than quadrupled the stores we have access to and we are seeing market growth in the fourth quarter of fiscal 2026. The launch of o…
Cost control and Right Sizing: Beginning in the fourth fiscal quarter of 2026, we implemented a plan targeting $100,000 to $150,000 in monthly cost savings, or approximately $1.2 to $1.8 million on an annualized basis. These are principally fixed-cost reductions and to date have included payroll red…
相对上期删除的文字 · 来源:10-Q · 2026-05-14
Multiple legislative measures have been introduced in the 119th Congress that would repeal, delay, or modify Section 781 of Public Law 119-37, or that would establish a federal regulatory framework for hemp-derived cannabinoid products. These include H.R. 6209 (repeal of Section 781); H.R. 7024 and …
On April 1, 2026, the Centers for Medicare & Medicaid Services (“CMS”) activated the Substance Access Beneficiary Engagement Incentive (“BEI”), under which approved participants in the ACO REACH Model and Enhancing Oncology Model may furnish eligible hemp-derived products to Medicare beneficiaries, …
On April 23, 2026, the Acting Attorney General issued a final order, effective April 28, 2026, rescheduling certain narrow categories of marijuana — FDA-approved drug products and state-licensed medical marijuana — from Schedule I to Schedule III under the Controlled Substances Act. An expedited DEA…
We remain focused on growing the Company in a smart, profitable manner along with appropriate cost controls.
We continued to pursue many strategies to grow our revenues and expand the scope of our business through the second quarter of 2026 and beyond:
如何读 10-Q 的风险因素(第 1A 项)
10-Q 的风险因素章节有三种常见形态,本页按其一分类展示:
- 指向(pointer) — 公司仅声明"无重大变化"并指向年度 10-K 的完整风险因素;本季没有自己的风险文本可对比。
- 部分更新(partial) — 公司写明"除下述外无重大变化",只更新部分风险;摘录展示的正是本季新增的内容。
- 全文重述(restated) — 本季重新给出完整风险因素。若上一季只是"指向",则无法逐段对比,本页会将其标为"本季全文重述"。
这只是对文件结构的客观描述,不构成对风险高低的判断。
数据来自 SEC EDGAR 两份申报文件的文本级对比 · 确定性计算(无 AI 生成内容)· 仅供参考 · 非投资建议